NCT04015622View on ClinicalTrials.gov

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 7, 2020

Primary Completion Date

April 1, 2026

Study Completion Date

December 1, 2026

Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
DRUG

Enzalutamide

Enzalutamide 160 mg PO OD

DRUG

Docetaxel

Docetaxel 75 mg/m2 IV every 3 weeks

Trial Locations (7)

V1Y 5L3

BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre), Kelowna

V2M 7E9

BC Cancer - Centre for the North, Prince George

V3V 1Z2

BC Cancer - Surrey Centre, Surrey

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

V5Z 4E6

BC Cancer - Vancouver Centre, Vancouver

V8R 6V5

BC Cancer - Victoria Centre, Victoria

N6A 5W9

London Health Sciences Centre, London

All Listed Sponsors
lead

British Columbia Cancer Agency

OTHER